Halozyme Therapeutics and Skye Bioscience have signed a non-exclusive global collaboration and license agreement enabling Skye to use Halozyme’s ENHANZE technology to develop a subcutaneous formulation of nimacimab for obesity, including evaluation of higher doses delivered via larger injection volumes. The deal includes development and commercial milestones and mid-single-digit royalties to Halozyme, with Skye targeting a Phase 2b obesity study in mid-2026 that will also test nimacimab in combination with a GLP-1 receptor agonist. Skye is already running a Phase 2a trial of nimacimab, a peripherally acting negative allosteric modulating antibody targeting CB1.
The strategic signal is clear: high-volume subcutaneous delivery is becoming a competitive lever in obesity, not just a convenience feature. As obesity regimens move toward biologics and combinations, the ability to deliver higher doses at home without infusion-center friction becomes a rate-limiting step. Halozyme, long validated in oncology and immunology, is positioning ENHANZE as infrastructure for the next wave of metabolic therapies. For Skye, the move de-risks an operational bottleneck—how to practically escalate doses of an antibody in a category where competitors are setting an efficacy bar with potent incretin-based agents—and accelerates optionality around combo strategies.
This matters now because the obesity market is rapidly evolving beyond incretin monotherapy toward multi-mechanistic regimens and differentiated patient segments. Patients and HCPs will prioritize regimens that couple meaningful incremental weight loss and metabolic benefit with manageable administration. If ENHANZE enables tolerable large-volume injections, subcutaneous nimacimab could avoid infusion logistics while testing whether peripheral CB1 blockade can deliver additive benefit without the CNS liabilities that derailed first-generation CB1 approaches. For payers, the value case will hinge on demonstrable incremental outcomes over GLP-1 alone, potential dose-sparing effects, and real-world adherence with larger-volume injections. Without such evidence, therapy stacking may face budget pressure in a class already under intense scrutiny for total cost of care.
For competitive teams, the partnership underscores two broader trends. First, delivery technology is becoming a differentiation axis in obesity, with hyaluronidase-enabled high-volume subcutaneous injections and on-body injectors competing to expand at-home administration. ENHANZE’s track record across multiple marketed products gives it credibility as companies push into higher viscosities and volumes. Second, platform licensors with royalty models are diversifying into obesity as a durable growth engine, shifting the balance of power toward enabling technologies that compress development timelines and unlock dose-ranging flexibility. Non-exclusivity suggests Halozyme intends to be a category utility, potentially partnering across mechanistic classes as antibody and peptide combinations proliferate.
Medical Affairs teams should prepare for pragmatic questions that will drive uptake: injection tolerability at higher volumes, site reactions and immunogenicity in real-world use, patient training for at-home administration, and the translational link between Phase 2 endpoints and outcomes that matter to payers such as reductions in obesity-related comorbidities. Regulatory strategies may need to incorporate delivery-bridging data that validate pharmacokinetics and exposure-response at higher subcutaneous doses, as well as combination-study designs aligned to payer evidence needs.
The next catalyst is proof that nimacimab can be delivered at higher subcutaneous doses with acceptable tolerability and that it meaningfully augments GLP-1 outcomes. If those signals emerge in 2026, expect intensified business development interest and a broader rush to lock in delivery partnerships. The open question is whether delivery innovation can move fast enough to support complex, multi-agent obesity regimens without breaking payer budgets—or whether the winning strategies will be those that marry combination efficacy with delivery that enables dose minimization and cost control.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
